{"count": 8, "results": [{"_id": "2200490", "pmid": 2200490, "title": "Hypertension in the elderly: a study of a combination of atenolol and nifedipine.", "journal": "Br J Clin Pract", "authors": ["Duckett GK", "Cheadle B"], "date": "1990-02-01T00:00:00Z", "meta_date_publication": "1990 Feb", "meta_volume": "44", "meta_issue": "2", "meta_pages": "52-4", "score": 50071.438, "text_hl": "@DISEASE_Hypertension @DISEASE_MESH:D006973 @@@Hypertension@@@ in the elderly: a study of a combination of @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ and @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@.", "citations": {"NLM": "Duckett GK, Cheadle B. Hypertension in the elderly: a study of a combination of atenolol and nifedipine. Br J Clin Pract. 1990 Feb;44(2):52-4. PMID: 2200490", "BibTeX": "@article{2200490, title={Hypertension in the elderly: a study of a combination of atenolol and nifedipine.}, author={Duckett GK and Cheadle B}, journal={Br J Clin Pract}, volume={44}, number={2}, pages={52-4}}"}}, {"_id": "2894883", "pmid": 2894883, "title": "Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee.", "journal": "Br Med J (Clin Res Ed)", "authors": ["Nifedipine-Atenolol Study Review Committee"], "date": "1988-02-13T00:00:00Z", "meta_date_publication": "1988 Feb 13", "meta_volume": "296", "meta_issue": "6620", "meta_pages": "468-72", "score": 50068.52, "text_hl": "Twenty six @SPECIES_9606 @@@patients@@@ (12%) were withdrawn because of adverse effects while taking @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@ compared with 19 (10%) taking @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@Flushing@@@ and @DISEASE_Tang_Hsi_Ryu_syndrome @DISEASE_MESH:C536897 @@@oedema@@@ were more common after the calcium antagonist, whereas @DISEASE_Diarrhea @DISEASE_MESH:D003967 @@@diarrhoea@@@ and @DISEASE_Dyspepsia @DISEASE_MESH:D004415 @@@dyspepsia@@@ were more common after @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Nifedipine-Atenolol Study Review Committee. Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee. Br Med J (Clin Res Ed). 1988 Feb 13;296(6620):468-72. PMID: 2894883", "BibTeX": "@article{2894883, title={Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee.}, author={Nifedipine-Atenolol Study Review Committee}, journal={Br Med J (Clin Res Ed)}, volume={296}, number={6620}, pages={468-72}}"}}, {"_id": "24099152", "pmid": 24099152, "title": "Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.", "journal": "Climacteric", "authors": ["Kujala SM", "Pöyhönen-Alho M", "Kaaja RJ"], "date": "2014-08-01T00:00:00Z", "doi": "10.3109/13697137.2013.842226", "meta_date_publication": "2014 Aug", "meta_volume": "17", "meta_issue": "4", "meta_pages": "356-62", "score": 50065.71, "text_hl": "Relief from @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@hot flushes@@@ was recorded in 43% of @SPECIES_9606 @@@women@@@ taking @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ and in 27% (not significant between the groups) of @CHEMICAL_moxonidine @CHEMICAL_MESH:C043482 @@@moxonidine@@@-treated @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Kujala SM, Pöyhönen-Alho M, Kaaja RJ. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women. Climacteric. 2014 Aug;17(4):356-62. PMID: 24099152", "BibTeX": "@article{24099152, title={Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.}, author={Kujala SM and Pöyhönen-Alho M and Kaaja RJ}, journal={Climacteric}, volume={17}, number={4}, pages={356-62}}"}}, {"_id": "3288467", "pmid": 3288467, "title": "Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study.", "journal": "Drugs", "authors": ["Anderton JL", "Vallance BD", "Stanley NN", "Crowe PF", "Mittra B", "Perks WH"], "date": "1988-01-01T00:00:00Z", "doi": "10.2165/00003495-198800354-00006", "meta_date_publication": "1988", "meta_volume": "35 Suppl 4", "meta_issue": "", "meta_pages": "22-6", "score": 50056.883, "text_hl": "Side effects were typical of those associated with @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@ or @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@Flushes@@@ and @DISEASE_Hot_Flashes @DISEASE_MESH:D019584 @@@hot sweats@@@, which were frequent with @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@, were significantly less (p less than 0.001) with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ or the combination.", "citations": {"NLM": "Anderton JL, Vallance BD, Stanley NN, Crowe PF, Mittra B, Perks WH. Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study. Drugs. 1988;35 Suppl 4():22-6. PMID: 3288467", "BibTeX": "@article{3288467, title={Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study.}, author={Anderton JL and Vallance BD and Stanley NN and Crowe PF and Mittra B and Perks WH}, journal={Drugs}, volume={35 Suppl 4}, pages={22-6}}"}}, {"_id": "2859865", "pmid": 2859865, "title": "Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.", "journal": "Arzneimittelforschung", "authors": ["Salvadeo A", "Villa G", "Segagni S", "Piazza V", "Picardi L", "Romano M", "Parini J"], "date": "1985-01-01T00:00:00Z", "meta_date_publication": "1985", "meta_volume": "35", "meta_issue": "3", "meta_pages": "623-5", "score": 50052.6, "text_hl": "During @CHEMICAL_cadralazine @CHEMICAL_MESH:C031877 @@@cadralazine@@@ treatment, heart rate was always significantly lower than before @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ alone; the most common side effects, many of which were already present during treatment with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ alone, included @DISEASE_Headache @DISEASE_MESH:D006261 @@@headache@@@, @DISEASE_Asthenia @DISEASE_MESH:D001247 @@@asthenia@@@, @DISEASE_Dizziness @DISEASE_MESH:D004244 @@@dizziness@@@, @DISEASE_Heart_Diseases @DISEASE_MESH:D006331 @@@palpitation@@@ and @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@, and tended to disappear spontaneously as therapy progressed. ", "citations": {"NLM": "Salvadeo A, Villa G, Segagni S, Piazza V, Picardi L, Romano M, Parini J. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension. Arzneimittelforschung. 1985;35(3):623-5. PMID: 2859865", "BibTeX": "@article{2859865, title={Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.}, author={Salvadeo A and Villa G and Segagni S and Piazza V and Picardi L and Romano M and Parini J}, journal={Arzneimittelforschung}, volume={35}, number={3}, pages={623-5}}"}}, {"_id": "2889810", "pmid": 2889810, "title": "Calcium antagonists: a review of the recent comparative trials.", "journal": "J Hypertens Suppl", "authors": ["Fitzsimons TJ"], "date": "1987-08-01T00:00:00Z", "meta_date_publication": "1987 Aug", "meta_volume": "5", "meta_issue": "3", "meta_pages": "S11-5", "score": 50052.254, "text_hl": "In one study involving 44 @SPECIES_9606 @@@patients@@@ (aged 20-70 years), side effects attributable to peripheral vasodilation secondary to @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@ therapy, e.g. @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ and @DISEASE_Sweat_Gland_Diseases @DISEASE_MESH:D013543 @@@sweats@@@, were significantly greater (P less than 0.05) with @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@ (n = 11) than with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ (n = 3).", "citations": {"NLM": "Fitzsimons TJ. Calcium antagonists: a review of the recent comparative trials. J Hypertens Suppl. 1987 Aug;5(3):S11-5. PMID: 2889810", "BibTeX": "@article{2889810, title={Calcium antagonists: a review of the recent comparative trials.}, author={Fitzsimons TJ}, journal={J Hypertens Suppl}, volume={5}, number={3}, pages={S11-5}}"}}, {"_id": "12180896", "pmid": 12180896, "title": "The management of rosacea.", "journal": "Am J Clin Dermatol", "authors": ["Rebora A"], "date": "2002-01-01T00:00:00Z", "doi": "10.2165/00128071-200203070-00005", "meta_date_publication": "2002", "meta_volume": "3", "meta_issue": "7", "meta_pages": "489-96", "score": 50046.58, "text_hl": "Beta-blockers, @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ in particular, are worthy of prophylactic trials examining their efficacy in treating the @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@flushing@@@ associated with @DISEASE_Rosacea @DISEASE_MESH:D012393 @@@rosacea@@@. ", "citations": {"NLM": "Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3(7):489-96. PMID: 12180896", "BibTeX": "@article{12180896, title={The management of rosacea.}, author={Rebora A}, journal={Am J Clin Dermatol}, volume={3}, number={7}, pages={489-96}}"}}, {"_id": "23539159", "pmid": 23539159, "title": "Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach.", "journal": "Ther Adv Respir Dis", "authors": ["Moua J", "Nussbaum E", "Liao E", "Randhawa IS"], "date": "2013-08-01T00:00:00Z", "doi": "10.1177/1753465813482744", "meta_date_publication": "2013 Aug", "meta_volume": "7", "meta_issue": "4", "meta_pages": "217-23", "score": 50046.117, "text_hl": "Very minimal adverse effects were observed with only one @SPECIES_9606 @@@patient@@@ reporting intermittent @<m>DISEASE_Flushing</m> @DISEASE_MESH:D005483 @@@facial flushing@@@. CONCLUSION: Beta-blockade, particularly with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, appears to successfully treat, if not resolve, recurrent @DISEASE_Hemoptysis @DISEASE_MESH:D006469 @@@hemoptysis@@@ refractory to conservative therapy in @DISEASE_Cystic_Fibrosis @DISEASE_MESH:D003550 @@@CF@@@. ", "citations": {"NLM": "Moua J, Nussbaum E, Liao E, Randhawa IS. Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach. Ther Adv Respir Dis. 2013 Aug;7(4):217-23. PMID: 23539159", "BibTeX": "@article{23539159, title={Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach.}, author={Moua J and Nussbaum E and Liao E and Randhawa IS}, journal={Ther Adv Respir Dis}, volume={7}, number={4}, pages={217-23}}"}}]}